BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nydegger A, Novak U, Kronig MN, Legros M, Zeerleder S, Banz Y, Bacher U, Pabst T. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers (Basel) 2021;13:6073. [PMID: 34885182 DOI: 10.3390/cancers13236073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Benoit A, B Boies MH, Déry N, M Garcia L, Simard M, Poirier M, Delage R, Lortal Canguilhem B, Doyle C, Larouche JF, Couture F, Lemieux C. CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study. Clin Lymphoma Myeloma Leuk 2022:S2152-2650(22)01779-7. [PMID: 36646606 DOI: 10.1016/j.clml.2022.12.015] [Reference Citation Analysis]
2 Borchmann S. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2022;2022:717-22. [PMID: 36485084 DOI: 10.1182/hematology.2022000364] [Reference Citation Analysis]
3 Gössi S, Bacher U, Haslebacher C, Nagler M, Suter F, Staehelin C, Novak U, Pabst T. Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy. Cancers 2022;14:3527. [DOI: 10.3390/cancers14143527] [Reference Citation Analysis]
4 Stoffel T, Bacher U, Banz Y, Daskalakis M, Novak U, Pabst T. BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study. JCM 2022;11:3748. [DOI: 10.3390/jcm11133748] [Reference Citation Analysis]
5 Wei Y, Wang Y, Li H, Wang C, Liu S, Huang Z, Wang G, Tao Y, Xia Y. A Nomogram to Predict Survival in Patients With Locoregional Recurrent Nasopharyngeal Carcinoma Receiving Comprehensive Treatment. Front Oncol 2022;12:892510. [DOI: 10.3389/fonc.2022.892510] [Reference Citation Analysis]
6 Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, Pabst T. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers 2022;14:2516. [DOI: 10.3390/cancers14102516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Seipel K, Porret N, Wiedemann G, Jeker B, Bacher VU, Pabst T. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. CIMB 2022;44:1463-71. [DOI: 10.3390/cimb44040098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]